Lei Guiyu, Wu Lili, Yin Yue, Zhang Shu, Wang Guyan
Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, 100730, People's Republic of China.
Center of Foot and Ankle Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
Local Reg Anesth. 2025 May 7;18:27-38. doi: 10.2147/LRA.S515510. eCollection 2025.
This study aims to assess and compare the effectiveness of perineural dexamethasone (DEX) and perineural dexmedetomidine (DEM) as adjuvant in popliteal sciatic and saphenous nerve blocks, focusing on the duration of analgesia and side effects following major foot and ankle surgeries.
Ninety patients scheduled for major foot and ankle surgeries under general anesthesia, who received popliteal sciatic and saphenous nerve blocks, were randomly assigned to one of three groups: (1) control group receiving 0.375% ropivacaine; (2) DEX group receiving 0.375% ropivacaine combined with 10 mg perineural dexamethasone; (3) DEM group receiving 0.375% ropivacaine combined with 0.75 μg/kg perineural dexmedetomidine. The primary outcome measured was the duration of analgesia, defined as the time from the administration of the nerve block to the onset of the first pain sensation in the surgical area. Secondary outcomes included opioid consumption within the first 48 hours post-surgery and the incidence of side effects such as hypotension and bradycardia. (Clinical trial registration number: ChiCTR2100048127).
The time until the first perception of pain was significantly extended in the DEX group (28.0 (3.3) hours) compared to the DEM group (24.1 (1.3) hours) and the control group (17.5 (3.5) hours, P<0.001). Additionally, opioid consumption within the first 24 hours was markedly reduced in both the DEX and DEM groups compared to the control group (P<0.001). However, opioid usage between 0 to 48 hours post-surgery showed no significant differences among the three groups. The DEM group experienced a higher incidence of hypotension and bradycardia compared to both the DEX and control group (P<0.001).
Both 10 mg dexamethasone and 0.75 µg/kg dexmedetomidine effectively prolonged analgesia in patients undergoing major foot and ankle surgery with a popliteal sciatic and saphenous nerve block. However, dexamethasone (10 mg) provided a significantly longer duration of analgesia compared to dexmedetomidine (0.75 µg/kg).
Chictr.org.cn identifier: ChiCTR2100048127.
本研究旨在评估和比较神经周围注射地塞米松(DEX)和右美托咪定(DEM)作为辅助药物用于腘窝坐骨神经和隐神经阻滞的有效性,重点关注足踝部大手术后的镇痛持续时间和副作用。
90例计划在全身麻醉下进行足踝部大手术并接受腘窝坐骨神经和隐神经阻滞的患者,被随机分为三组:(1)对照组接受0.375%罗哌卡因;(2)DEX组接受0.375%罗哌卡因联合10 mg神经周围注射地塞米松;(3)DEM组接受0.375%罗哌卡因联合0.75 μg/kg神经周围注射右美托咪定。主要观察指标为镇痛持续时间,定义为从神经阻滞给药至手术区域首次出现疼痛感觉的时间。次要观察指标包括术后48小时内的阿片类药物消耗量以及低血压和心动过缓等副作用的发生率。(临床试验注册号:ChiCTR2100048127)
与DEM组(24.1(1.3)小时)和对照组(17.5(3.5)小时,P<0.001)相比,DEX组首次感觉到疼痛的时间显著延长(28.0(3.3)小时)。此外,与对照组相比,DEX组和DEM组术后24小时内的阿片类药物消耗量均显著减少(P<0.001)。然而,术后0至48小时的阿片类药物使用量在三组之间无显著差异。与DEX组和对照组相比,DEM组低血压和心动过缓的发生率更高(P<0.001)。
10 mg地塞米松和0.75 μg/kg右美托咪定都能有效延长接受腘窝坐骨神经和隐神经阻滞的足踝部大手术患者的镇痛时间。然而,地塞米松(10 mg)的镇痛持续时间明显长于右美托咪定(0.75 μg/kg)。
中国临床试验注册中心标识符:ChiCTR2100048127。